Cargando…

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer

Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. However, the potential therapeutic effect of osimertinib combined with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Nannan, Wang, Linlin, Meng, Xiangjiao, Wang, Jia, Zhu, Lifang, Liu, Changting, Li, Shaorong, Zheng, Li, Yang, Zhenfan, Xing, Ligang, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278463/ https://www.ncbi.nlm.nih.gov/pubmed/30365094 http://dx.doi.org/10.3892/or.2018.6803

Ejemplares similares

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
por: Zhang, Xiao-Yu, et al.
Publicado: (2016)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
por: Chen, Jingyu, et al.
Publicado: (2022)

AZD9291-induced Acute Interstitial Lung Disease
por: Nie, Ke-Ke, et al.
Publicado: (2016)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
por: Tang, Zheng-Hai, et al.
Publicado: (2016)

A case report of toxic epidermal necrolysis associated with AZD-9291
por: Wang, Jie, et al.
Publicado: (2018)

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
por: Huang, Jing, et al.
Publicado: (2018)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020)

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
por: Li, Lin, et al.
Publicado: (2017)

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2019)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2020)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
por: Liu, Kejun, et al.
Publicado: (2021)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
por: Buzard, Blake, et al.
Publicado: (2023)

Primary resistance to osimertinib despite acquired T790M
por: Chang, Ling‐Kai, et al.
Publicado: (2020)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
por: Gu, Yu, et al.
Publicado: (2020)

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
por: Chen, Tianxiang, et al.
Publicado: (2019)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
por: Li, Chenguang, et al.
Publicado: (2018)

Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
por: Cao, Yabing, et al.
Publicado: (2019)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_07kuulu1n5obspodv69200d8ea